Analytical Data
-
Gene name
GP1BB
- Application
-
Alternative Names
GP1BB；Platelet glycoProtein Ib beta chain
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P13224-1
-
Expression Region
1-147aa
-
AA Sequence
MGSGPRGALS LLLLLLAPPS RPAAGCPAPC SCAGTLVDCG RRGLTWASLP TAFPVDTTEL VLTGNNLTAL PPGLLDALPA LRTAHLGANP WRCDCRLVPL RAWLAGRPER APYRDLRCVA PPALRGRLLP YLAEDELRAA CAPGPLC
-
Molecular Weight
14 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
GP1BB is a crucial component in the study of platelet biology and thrombosis. It is a part of the glycoprotein (GP) receptor complex on the platelet surface, specifically associated with GP1b, which plays a vital role in mediating interactions between platelets and the vascular endothelium. Research into GP1BB is primarily driven by its implications in various pathological conditions, including bleeding disorders and thrombotic diseases. Mutations or deficiencies in GP1BB can lead to Bernard-Soulier syndrome, a genetic condition characterized by prolonged bleeding due to impaired platelet function. Understanding the structure-function relationship of GP1BB can provide insights into the mechanisms underlying platelet activation and aggregation, essential processes in hemostasis. Furthermore, GP1BB serves as a potential therapeutic target for the development of new anticoagulant therapies, aimed at mitigating thrombotic events in cardiovascular diseases. Advances in recombinant protein technologies have paved the way for the production and characterization of GP1BB, enabling detailed studies of its biochemical properties and interactions. Ultimately, this research holds promise not only for elucidating the fundamental biology of platelets but also for translating findings into clinical approaches that enhance patient outcomes in disorders related to abnormal platelet function.
